Prognosis of intracranial meningiomas with TERTp mutation: systematic review with meta-analysis
Clicks: 2
ID: 322883
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #3 of 40 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Telomerase reverse transcriptase promoter (TERTp; C228T/C250T) mutations are incorporated into the WHO 2021 classification of meningiomas (20–30% in Grade 3)1,5,6,7 as criteria for higher grade designation, despite heterogeneous evidence1,2,3,4 regarding their independent prognostic value. Objectives To evaluate the association between TERTp mutations and overall survival (OS) and progression-free survival (PFS) in patients with intracranial meningiomas. Methods A systematic review and meta-analysis of clinical-pathological cohort studies comparing TERTp-mutated and wild-type meningiomas was conducted. Studies were identified through searches of PubMed, Embase, and Web of Science. Survival outcomes were synthesized using hazard ratios (HRs) and median survival estimates. Results Thirteen studies were included. Meta-analyses comprised four studies for progression-free survival by hazard ratio, five for overall survival by hazard ratio, five for progression-free survival by mean difference (eight comparisons), and five for overall survival by mean difference. Sensitivity analyses excluded Maas et al. (2021), Spiegl-Kreineck et al. (2018), and Mellai et al. (2021) from the progression-free survival mean-difference, overall survival hazard-ratio, and overall survival mean-difference models, respectively; no study was excluded from the progression-free survival hazard-ratio model. Conclusions TERTp promoter mutations identify a biologically aggressive meningioma subgroup with markedly reduced survival, supporting their role as prognostic biomarkers. However, their isolated use for tumor reclassification should be interpreted cautiously and integrated with additional molecular features2. Funding No external funding was received. Registration PROSPERO platform (No. CRD420251135452).
| Reference Key |
openalex_W7171491219
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Giovana Clausson Bitolo, Christopher Aquino Pereira Lima, P. Nogueira, Bianca Gomes Wanderley, Mateus Dal Fabbro, Marcos Vinícius Calfat Maldaun, Cleiton Formentin |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag073
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.